Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Leiomyosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Breast Cancer|Alveolar Soft Part Sarcoma|Primitive Neuroectodermal Tumors|Gliosarcoma|Embryonal Rhabdomyosarcoma|Synovial Sarcoma|Alveolar Rhabdomyosarcoma|Osteosarcoma|Adenocarcinoma|Neurofibrosarcoma|Sarcoma, Ewing|Liposarcoma|Hemangiosarcoma|Bronchiolo-Alveolar Adenocarcinoma|Mesothelioma|Neuroendocrine Tumors|Prostate Cancer|Adrenocortical Carcinoma|Kidney Cancer|Head and Neck Cancer|Non-Small-Cell Lung Cancer|Liver Cancer|Squamous Cell Carcinoma|Soft Tissue Cancer|Colorectal Cancer|Esophageal Cancer|Retinoblastoma|Rhabdomyosarcoma|Neuroendocrine Carcinoma|Large Cell Carcinoma|Wilms Tumor|Pancreatic Cancer|Hepatoblastoma|Peritoneal Cancer|Embryonal Carcinoma|Uveal Melanoma|Neuroblastoma|Gastrointestinal Cancer|Small Cell Lung Cancer|Hepatocellular Carcinoma|Male Breast Cancer
Phase 1: Oncology Solid Tumor Unspecified|Primitive Neuroectodermal Tumors|Sarcoma, Ewing|Peripheral Neuroectodermal Tumors, Primitive|Hepatocellular Carcinoma|Thrombocytopenia|Hyperglycemia|Neutropenia|Pinealoma|Glioma|Anemia|Hypertension|Carcinoid Tumor|Medullary Carcinoma|Carcinoma, Merkel Cell|Somatostatinoma|Carotid Body Tumor|Glucagonoma|Neuroendocrine Carcinoma|Gastrointestinal Cancer|Paraganglioma|Pancreatic Cancer|Gastrinoma|Malignant Carcinoid Syndrome|Insulinoma|Islet Cell Carcinoma|Neuroendocrine Tumors
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2011-03039 | P2 |
Completed |
Squamous Cell Carcinoma|Head and Neck Cancer |
2018-08-15 |
|
| BATTLE-FL | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-15 |
|
| NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
|
| 10-C-0146 | P2 |
Completed |
Mesothelioma|Peritoneal Cancer |
2016-08-13 |